Xiong, Y
no trials have been conducted in BN, and high rates of diagnostic crossover to anorexia nervosa (AN) raise additional safety and ethical concerns [22, 23]
Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
At Stanton Chase, we're more than just an executive search and leadership consulting firm
Glucose & Metabolic Control Like tirzepatide, it strongly lowers HbA1c and improves insulin sensitivity
If you must stop (side effects, cost, pregnancy), work with your doctor to minimize regain through lifestyle strategies, but expect some weight return